desloratadine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 814 100643-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SCH-34117
  • SCH 34117
  • desloratadine
  • azomyr
  • delopedil
  • descarboethoxyloratadine
  • descarboethoxyloratidine
  • neoclarityn
major metabolite of loratadine
  • Molecular weight: 310.83
  • Formula: C19H19ClN2
  • CLOGP: 3.83
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 24.92
  • ALOGS: -4.90
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 2001 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 155.88 12.39 111 14820 37565 50552628
Urticaria 109.23 12.39 161 14770 129400 50460793
Drug reaction with eosinophilia and systemic symptoms 58.79 12.39 56 14875 28368 50561825
Allergy test positive 52.82 12.39 14 14917 391 50589802
Erythema 50.17 12.39 124 14807 146290 50443903
Hyponatraemia 48.34 12.39 95 14836 96044 50494149
Toxic skin eruption 43.86 12.39 32 14899 11219 50578974
Pruritus 43.44 12.39 182 14749 283386 50306807
Hallucination, auditory 42.93 12.39 31 14900 10697 50579496
Dermatitis bullous 41.35 12.39 26 14905 7147 50583046
Haemangioma congenital 37.99 12.39 11 14920 428 50589765
Death 37.54 12.39 25 14906 325354 50264839
Terminal dribbling 36.53 12.39 6 14925 11 50590182
Eczema 34.69 12.39 38 14893 22664 50567529
Paranoia 32.76 12.39 26 14905 10322 50579871
Rheumatoid arthritis 31.97 12.39 10 14921 202540 50387653
Drug intolerance 30.88 12.39 13 14918 219091 50371102
Victim of chemical submission 29.17 12.39 8 14923 255 50589938
Blood immunoglobulin E increased 28.72 12.39 14 14917 2345 50587848
Completed suicide 28.27 12.39 3 14928 131886 50458307
Intentional overdose 28.11 12.39 59 14872 62445 50527748
Cerebral thrombosis 27.54 12.39 12 14919 1556 50588637
Face oedema 27.50 12.39 30 14901 17809 50572384
Intentional self-injury 27.47 12.39 34 14897 23078 50567115
Nasal ulcer 26.72 12.39 12 14919 1671 50588522
Systemic lupus erythematosus 25.96 12.39 5 14926 140617 50449576
Tooth injury 25.82 12.39 10 14921 961 50589232
Skin dystrophy 25.26 12.39 5 14926 35 50590158
Type IV hypersensitivity reaction 25.13 12.39 13 14918 2469 50587724
Aggression 24.99 12.39 31 14900 21085 50569108
Oxalosis 24.56 12.39 5 14926 41 50590152
Gestational hypertension 23.80 12.39 12 14919 2161 50588032
Somnolence 23.29 12.39 99 14832 154886 50435307
Urticaria thermal 22.59 12.39 6 14925 169 50590024
Drug ineffective 22.43 12.39 146 14785 819187 49771006
Burn oral cavity 22.40 12.39 5 14926 66 50590127
Hyperkalaemia 22.33 12.39 46 14885 48043 50542150
Endocrine ophthalmopathy 22.18 12.39 7 14924 366 50589827
Joint swelling 21.96 12.39 24 14907 245262 50344931
Wound 21.21 12.39 3 14928 105791 50484402
Tongue oedema 19.86 12.39 13 14918 3826 50586367
Synovitis 19.74 12.39 6 14925 123859 50466334
Dermatitis exfoliative generalised 19.72 12.39 12 14919 3114 50587079
Hyperoxaluria 19.32 12.39 5 14926 127 50590066
Therapeutic product effect decreased 19.27 12.39 8 14923 136042 50454151
Hepatocellular injury 18.65 12.39 30 14901 25917 50564276
Inflammatory bowel disease 18.63 12.39 12 14919 3438 50586755
Acute kidney injury 18.59 12.39 123 14808 227935 50362258
Guttate psoriasis 18.21 12.39 6 14925 360 50589833
Treatment failure 18.08 12.39 9 14922 137628 50452565
Nightmare 18.06 12.39 23 14908 16063 50574130
HLA-B*27 positive 17.28 12.39 5 14926 194 50589999
Rash erythematous 16.96 12.39 34 14897 34818 50555375
Eosinophilia 16.86 12.39 24 14907 18628 50571565
Keratopathy 16.77 12.39 6 14925 462 50589731
Rash maculo-papular 16.73 12.39 29 14902 26612 50563581
Urine oxalate increased 16.42 12.39 5 14926 232 50589961
Pain 16.38 12.39 102 14829 578801 50011392
Arteriospasm coronary 16.34 12.39 11 14920 3391 50586802
Upper respiratory tract infection bacterial 16.18 12.39 4 14927 84 50590109
Asthma 15.75 12.39 60 14871 89277 50500916
Arrhythmia 15.74 12.39 32 14899 33100 50557093
Abortion 15.61 12.39 9 14922 2115 50588078
Photosensitivity reaction 15.35 12.39 19 14912 12892 50577301
Patent ductus arteriosus 15.19 12.39 11 14920 3809 50586384
Subretinal haematoma 15.15 12.39 3 14928 21 50590172
Nasal pruritus 14.96 12.39 5 14926 314 50589879
Amnestic disorder 14.96 12.39 5 14926 314 50589879
Hypersensitivity pneumonitis 14.87 12.39 9 14922 2313 50587880
Lip oedema 14.57 12.39 10 14921 3183 50587010
Intraocular haematoma 14.49 12.39 3 14928 27 50590166
Food intolerance 14.44 12.39 9 14922 2435 50587758
Feeling hot 14.24 12.39 34 14897 39168 50551025
Anaphylactic shock 14.07 12.39 23 14908 20132 50570061
Psychotic disorder 14.04 12.39 24 14907 21788 50568405
Contraindicated product administered 13.96 12.39 14 14917 148944 50441249
Vitamin D deficiency 13.91 12.39 17 14914 11385 50578808
Onycholysis 13.57 12.39 7 14924 1321 50588872
Pharyngeal oedema 13.49 12.39 18 14913 13147 50577046
White blood cell count decreased 13.38 12.39 9 14922 116713 50473480
Fixed eruption 13.38 12.39 6 14925 833 50589360
Systolic hypertension 13.36 12.39 5 14926 437 50589756
Hepatic cytolysis 13.14 12.39 14 14917 8089 50582104
Drug dose titration not performed 13.13 12.39 5 14926 459 50589734
Pancoast's syndrome 13.08 12.39 3 14928 45 50590148
Product use in unapproved indication 13.00 12.39 68 14863 115751 50474442
Eyelid erosion 12.96 12.39 3 14928 47 50590146
Toxic shock syndrome 12.84 12.39 5 14926 487 50589706
Vertigo 12.82 12.39 39 14892 51793 50538400
Swelling 12.73 12.39 25 14906 200847 50389346
Urticaria chronic 12.68 12.39 5 14926 504 50589689
Hernia hiatus repair 12.68 12.39 3 14928 52 50590141
Hepatic lesion 12.53 12.39 10 14921 3998 50586195

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Eosinophilia 58.12 14.10 47 7532 22114 29544834
Toxic skin eruption 52.14 14.10 32 7547 9725 29557223
Rash maculo-papular 50.34 14.10 45 7534 24244 29542704
Dermatitis bullous 46.66 14.10 25 7554 5881 29561067
Death 41.49 14.10 18 7561 342066 29224882
Hepatic haematoma 40.68 14.10 11 7568 384 29566564
Xerosis 38.33 14.10 11 7568 479 29566469
Hyperkaliuria 37.67 14.10 8 7571 96 29566852
Intentional overdose 36.30 14.10 47 7532 38481 29528467
Eczema 35.55 14.10 29 7550 13797 29553151
Corneal abscess 35.06 14.10 6 7573 19 29566929
Urticaria 32.98 14.10 54 7525 54606 29512342
Electrocardiogram QT prolonged 32.36 14.10 43 7536 36094 29530854
Pruritus 30.73 14.10 82 7497 116767 29450181
Rash pustular 29.25 14.10 17 7562 4674 29562274
Miosis 27.61 14.10 20 7559 7989 29558959
Purpura 25.08 14.10 20 7559 9212 29557736
Blood immunoglobulin E decreased 25.05 14.10 5 7574 43 29566905
Keratitis 25.04 14.10 10 7569 1202 29565746
Angioedema 24.11 14.10 35 7544 31880 29535068
Acute generalised exanthematous pustulosis 24.08 14.10 16 7563 5567 29561381
Cholangiocarcinoma 23.74 14.10 9 7570 941 29566007
Prurigo 23.57 14.10 8 7571 608 29566340
Oedema genital 23.21 14.10 7 7572 363 29566585
Arrhythmia 23.16 14.10 34 7545 31279 29535669
Oral dysaesthesia 22.15 14.10 5 7574 81 29566867
Bulbar palsy 21.57 14.10 6 7573 233 29566715
Eyelid ptosis congenital 21.55 14.10 5 7574 92 29566856
Type III immune complex mediated reaction 21.21 14.10 6 7573 248 29566700
Myoglobin blood increased 20.25 14.10 10 7569 1985 29564963
Dermatitis exfoliative 19.80 14.10 15 7564 6410 29560538
Pemphigoid 19.69 14.10 16 7563 7565 29559383
Dermatitis psoriasiform 18.79 14.10 8 7571 1130 29565818
Hepatic cytolysis 18.35 14.10 16 7563 8331 29558617
Retinopathy 18.23 14.10 9 7570 1786 29565162
Spermatic cord disorder 17.65 14.10 3 7576 9 29566939
Rhinitis allergic 17.48 14.10 10 7569 2670 29564278
Hyperlipasaemia 17.36 14.10 6 7573 481 29566467
Rhabdomyolysis 17.31 14.10 44 7535 60764 29506184
Hypertrophic cardiomyopathy 17.28 14.10 7 7572 872 29566076
Wrong product administered 17.20 14.10 12 7567 4519 29562429
Purulent pericarditis 16.98 14.10 3 7576 12 29566936
Rash erythematous 16.80 14.10 24 7555 21538 29545410
Vasoplegia syndrome 16.63 14.10 8 7571 1500 29565448
Intentional self-injury 16.34 14.10 18 7561 12443 29554505
Wrong patient received product 16.19 14.10 9 7570 2273 29564675
Coma 16.18 14.10 33 7546 39417 29527531
Asthma 15.93 14.10 30 7549 33819 29533129
Disease prodromal stage 15.84 14.10 3 7576 19 29566929
Cerebral venous thrombosis 15.78 14.10 6 7573 632 29566316
Pemphigus 15.37 14.10 7 7572 1161 29565787
Neonatal pneumonia 15.04 14.10 4 7575 131 29566817
Vascular cognitive impairment 14.53 14.10 3 7576 31 29566917

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 137.39 11.93 127 19010 61694 64417901
Urticaria 131.99 11.93 189 18948 147128 64332467
Toxic skin eruption 82.13 11.93 58 19079 19226 64460369
Dermatitis bullous 80.28 11.93 48 19089 12006 64467589
Pruritus 72.21 11.93 230 18907 312170 64167425
Eosinophilia 69.06 11.93 70 19067 38006 64441589
Eczema 67.81 11.93 62 19075 29658 64449937
Death 66.66 11.93 30 19107 482675 63996920
Rash maculo-papular 58.56 11.93 71 19066 46955 64432640
Allergy test positive 56.43 11.93 15 19122 421 64479174
Hallucination, auditory 43.93 11.93 38 19099 16901 64462694
Erythema 43.37 11.93 138 18999 186932 64292663
Drug reaction with eosinophilia and systemic symptoms 43.32 11.93 66 19071 54151 64425444
Completed suicide 39.66 11.93 9 19128 224405 64255190
Arrhythmia 37.52 11.93 61 19076 52883 64426712
Terminal dribbling 36.49 11.93 6 19131 11 64479584
Hyponatraemia 35.81 11.93 111 19026 148228 64331367
Rash erythematous 35.78 11.93 57 19080 48576 64431019
Electrocardiogram QT prolonged 35.45 11.93 75 19062 79373 64400222
Face oedema 35.16 11.93 40 19097 24721 64454874
Somnolence 32.50 11.93 133 19004 203512 64276083
Aggression 32.40 11.93 53 19084 46179 64433416
Hyperkaliuria 32.35 11.93 8 19129 167 64479428
Hepatic cytolysis 31.44 11.93 29 19108 14020 64465575
Hepatic haematoma 31.07 11.93 11 19126 817 64478778
Intentional overdose 30.29 11.93 76 19061 89868 64389727
Blood immunoglobulin E increased 30.08 11.93 17 19120 3827 64475768
Corneal abscess 28.65 11.93 6 19131 57 64479538
Drug intolerance 28.65 11.93 10 19127 187982 64291613
Victim of chemical submission 28.08 11.93 8 19129 292 64479303
Nasal ulcer 27.78 11.93 12 19125 1514 64478081
Gestational hypertension 26.67 11.93 12 19125 1669 64477926
Cerebral thrombosis 26.65 11.93 13 19124 2169 64477426
Nightmare 26.62 11.93 32 19105 20961 64458634
Rheumatoid arthritis 26.33 11.93 8 19129 164286 64315309
Acute generalised exanthematous pustulosis 25.76 11.93 26 19111 14032 64465563
Xerosis 25.70 11.93 10 19127 967 64478628
Oedema genital 24.64 11.93 8 19129 456 64479139
Paranoia 24.21 11.93 27 19110 16325 64463270
Hepatocellular injury 24.11 11.93 46 19091 45189 64434406
Skin dystrophy 23.92 11.93 5 19132 47 64479548
Type IV hypersensitivity reaction 23.75 11.93 14 19123 3408 64476187
Prurigo 23.58 11.93 10 19127 1207 64478388
Burn oral cavity 22.81 11.93 5 19132 60 64479535
Tooth injury 22.49 11.93 10 19127 1353 64478242
Urticaria thermal 22.38 11.93 6 19131 174 64479421
Vertigo 22.14 11.93 52 19085 58959 64420636
Endocrine ophthalmopathy 21.34 11.93 7 19130 412 64479183
Hyperkalaemia 21.07 11.93 72 19065 101057 64378538
HLA-B*27 positive 20.97 11.93 5 19132 89 64479506
Oxalosis 20.33 11.93 5 19132 102 64479493
Abortion 20.17 11.93 9 19128 1227 64478368
Bulbar palsy 20.16 11.93 6 19131 256 64479339
Miosis 19.80 11.93 22 19115 13244 64466351
Purpura 19.79 11.93 25 19112 17221 64462374
Platelet count decreased 19.35 11.93 13 19124 167698 64311897
Type III immune complex mediated reaction 19.16 11.93 7 19130 569 64479026
Asthma 19.15 11.93 67 19070 95158 64384437
Tongue oedema 18.78 11.93 15 19122 5975 64473620
Rhinitis allergic 18.71 11.93 17 19120 8061 64471534
Serum amyloid A protein increased 18.65 11.93 5 19132 145 64479450
White blood cell count decreased 18.52 11.93 12 19125 157825 64321770
Cholestasis 18.45 11.93 41 19096 44831 64434764
Inflammatory bowel disease 17.83 11.93 13 19124 4525 64475070
Guttate psoriasis 17.64 11.93 6 19131 395 64479200
Sepsis 17.26 11.93 26 19111 230315 64249280
Rhabdomyolysis 17.13 11.93 63 19074 91663 64387932
Cerebral venous thrombosis 16.98 11.93 10 19127 2431 64477164
Dermatitis exfoliative 16.91 11.93 18 19119 10334 64469261
Dermatitis exfoliative generalised 16.83 11.93 14 19123 5902 64473693
Keratitis 16.78 11.93 11 19126 3226 64476369
Acute kidney injury 16.67 11.93 205 18932 449035 64030560
Urine oxalate increased 16.54 11.93 5 19132 225 64479370
Pancreatitis acute 16.33 11.93 38 19099 42817 64436778
Cholangiocarcinoma 15.99 11.93 9 19128 2009 64477586
Myoglobin blood increased 15.89 11.93 10 19127 2737 64476858
Rash pustular 15.81 11.93 17 19120 9868 64469727
Feeling hot 15.80 11.93 39 19098 45624 64433971
Photosensitivity reaction 15.76 11.93 23 19114 18150 64461445
Hyperoxaluria 15.73 11.93 5 19132 266 64479329
Arteriospasm coronary 15.69 11.93 13 19124 5452 64474143
Hyperlipasaemia 15.36 11.93 7 19130 1003 64478592
Hypersensitivity vasculitis 15.21 11.93 14 19123 6747 64472848
Anaphylactic shock 15.13 11.93 30 19107 30298 64449297
Upper respiratory tract infection bacterial 15.06 11.93 4 19133 112 64479483
Disease progression 15.02 11.93 12 19125 141668 64337927
Onycholysis 14.95 11.93 8 19129 1618 64477977
Therapeutic product effect incomplete 14.92 11.93 6 19131 103476 64376119
Lip oedema 14.18 11.93 12 19125 5177 64474418
Retinopathy 14.04 11.93 10 19127 3355 64476240
Vascular cognitive impairment 13.93 11.93 3 19134 33 64479562
Synovitis 13.88 11.93 6 19131 99084 64380511
Altered state of consciousness 13.78 11.93 33 19104 37869 64441726
Drug level increased 13.78 11.93 31 19106 34165 64445430
Keratopathy 13.76 11.93 6 19131 774 64478821
Oral dysaesthesia 13.71 11.93 4 19133 159 64479436
Pemphigoid 13.61 11.93 18 19119 12968 64466627
Coronavirus infection 13.52 11.93 12 19125 5518 64474077
Urticaria chronic 13.24 11.93 5 19132 446 64479149
Therapeutic product effect decreased 13.22 11.93 9 19128 115342 64364253
Dermatitis psoriasiform 12.89 11.93 8 19129 2138 64477457
Cryopyrin associated periodic syndrome 12.77 11.93 3 19134 50 64479545
Nutritional condition abnormal 12.54 11.93 6 19131 960 64478635
Hyperthermia 12.51 11.93 19 19118 15531 64464064
Febrile neutropenia 12.37 11.93 23 19114 187634 64291961
Purulent pericarditis 12.25 11.93 3 19134 60 64479535
Acute haemorrhagic oedema of infancy 12.25 11.93 3 19134 60 64479535
Amnestic disorder 12.20 11.93 5 19132 554 64479041
Hypersensitivity pneumonitis 12.11 11.93 9 19128 3223 64476372
Eyelid erosion 11.98 11.93 3 19134 66 64479529
Neutrophil count decreased 11.93 11.93 4 19133 77192 64402403

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AX27 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:50857 anti-allergic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic urticaria indication 40178009 DOID:10612
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 2.48 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.96 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.03 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.55 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.80 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.00 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.19 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.97 DRUG MATRIX
Histamine H4 receptor GPCR IC50 4.80 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 7.74 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 7.60 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.49 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 7.70 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.30 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.51 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 4.37 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 5.70 DRUG MATRIX

External reference:

IDSource
4021292 VUID
N0000148729 NUI
D03693 KEGG_DRUG
275635 RXNORM
4021292 VANDF
C0908935 UMLSCUI
CHEBI:291342 CHEBI
CHEMBL1172 ChEMBL_ID
DB00967 DRUGBANK_ID
C121345 MESH_SUPPLEMENTAL_RECORD_UI
124087 PUBCHEM_CID
7157 IUPHAR_LIGAND_ID
7817 INN_ID
FVF865388R UNII
16243 MMSL
42606 MMSL
51632 MMSL
83662 MMSL
d04785 MMSL
009081 NDDF
134506008 SNOMEDCT_US
396015008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 21695-815 TABLET, FILM COATED 5 mg ORAL NDA 23 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 42291-240 TABLET 5 mg ORAL ANDA 26 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 50090-0765 TABLET, FILM COATED 5 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3975 TABLET 5 mg ORAL ANDA 30 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-4794 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4624 TABLET, FILM COATED 5 mg ORAL NDA 12 sections
Clarinex-D 12 Hour HUMAN PRESCRIPTION DRUG LABEL 2 54868-5708 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-360 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-551 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62250-619 TABLET 5 mg ORAL ANDA 25 sections
Desloratadine Human Prescription Drug Label 1 62756-523 TABLET, FILM COATED 5 mg ORAL ANDA 28 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 68180-153 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 69543-107 TABLET 5 mg ORAL ANDA 29 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1000 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections